abiraterone

November 13, 2019

Phase 1 DRGT-45 Trial Doses First Patient With New Oral Formulation of Abiraterone Acetate

News

A Phase 1 clinical trial testing DRGT-45 — a new oral formulation of abiraterone acetate — in men with prostate cancer has dosed its first participant, the treatment’s developer, Druggability ... Read more

July 9, 2018

Prostreat Seen as Better Than Current Therapies at Stopping Aggressive Prostate Cancer in Mice

News

NucleoBio’s investigative therapy Prostreat was seen to be better at preventing the growth and spread of metastatic castration-resistant prostate cancer than currently available hormone therapies, a mouse study showed. The ... Read more

June 14, 2018

Zytiga Rejected in England as First-line Treatment for Newly Diagnosed Advanced Prostate Cancer

News

Janssen’s medication Zytiga (abiraterone) was recently rejected as a first-line treatment for newly diagnosed advanced prostate cancer on the National Health Service (NHS) in England following an initial draft recommendation from the National ... Read more

October 20, 2017October 21, 2017

Trovagene’s PCM-075 Increases Zytiga’s Punch Against Prostate Cancer, Studies Show

News

Trovagene’s enzyme inhibitor PCM-075 increases the punch of the prostate cancer therapy Zytiga (abiraterone), preclinical-trial studies show. PCM-075 is a selective polo-like kinase 1 (PLK1) inhibitor. It inhibits a protein called PLK1, whose levels ... Read more

June 30, 2017

Galeterone Study Sheds Light on Promising Next-Gen Therapies for Advanced Prostate Cancer

News

A new study shows how galeterone is metabolized in the body, suggesting that it shares similarities with other steroidal anti-androgen drugs used to treat advanced prostate cancer. The finding could lay ... Read more

January 9, 2017

Zenith Recruiting Metastatic Prostate Cancer Patients for New Clinical Trial

News

Zenith Epigenetics has started a Phase 1b clinical trial to assess the safety and tolerability of its orally administered BET inhibitor ZEN-3694 in combination with Xtandi (enzalutamide) in metastatic castration-resistant prostate ... Read more

July 25, 2016July 29, 2016

AR Protein in Prostate Cancer Detected with New Imaging Technique

News

Researchers have developed a new imaging technique that can identify variants of the androgen receptors that do not respond to current androgen-deprivation therapies. The discovery could lead to better clinical management of patients ... Read more

June 8, 2016June 8, 2016

Scientists Identify Biomarker for Advanced Prostate Cancer as Specific Androgen Receptor in Circulating Cancer Cells

News

Expression of the nuclear androgen-receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) found in the blood of patients with advanced prostate cancer predicts the patients will fail to respond ... Read more

December 14, 2015December 14, 2015

NICE Issues Draft Guidance on Astellas’ Xtandi and Janssen’s Zytiga for Prostate Cancer Treatment

News

NICE issued its final draft guidance recommending enzalutamide (Xtandi, by Astellas Pharma) for prostate cancer (PC) patients who have already tried first-line treatments with no success, for those who have none ... Read more

February 11, 2015February 11, 2015

Abiraterone Proves Efficient Against Prostate Cancer

News

According to two recent studies, abiraterone, a drug for prostate cancer treatment, was found to increase survival in patients with advanced prostate cancer when given before chemotherapy. These encouraging results were ... Read more